Panwalker A P, Giamarellou H, Jackson G G
Antimicrob Agents Chemother. 1976 Mar;9(3):502-5. doi: 10.1128/AAC.9.3.502.
Cinoxacin, a new synthetic antibacterial agent with in vitro activity against all species of Enterobacteriaceae, was used in the treatment of urinary tract infections in 20 patients. The dose of cinoxacin was 250 mg orally every 6 h for 10 days. The etiological agents were Escherichia coli in fifteen, Klebsiella-Enterobacter in five, Proteus mirabilis in two, and Providencia in one. The minimal inhibitory concentration for these organisms ranged from 2 to 64 mug/ml. Eleven of the 20 patients had renal involvement by defined criteria, whereas the remaining nine were considered to have bladder bacilluria. The initial strain was eradicated during and immediately after treatment in 19 of 20 cases. At 6 weeks, 65% had sterile urine. Bactericidal urine levels of cinoxacin were obtained in all patients. No significant hematological, renal, hepatic, or gastroenterologic toxicity was noted. Cinoxacin appears to be a safe and useful drug in the treatment of urinary tract infections caused by Enterobacteriaceae.
西诺沙星是一种新型合成抗菌剂，对所有肠杆菌科细菌均具有体外活性，曾用于治疗20例尿路感染患者。西诺沙星的剂量为口服250毫克，每6小时一次，共10天。病原体为大肠杆菌15例、克雷伯菌-肠杆菌属5例、奇异变形杆菌2例、普罗威登斯菌1例。这些菌株的最低抑菌浓度范围为2至64微克/毫升。20例患者中有11例根据明确标准有肾脏受累，其余9例被认为患有膀胱菌尿症。20例中有19例在治疗期间及治疗后立即清除了初始菌株。在6周时，65%的患者尿液无菌。所有患者均获得了西诺沙星的杀菌尿浓度。未观察到明显的血液学、肾脏、肝脏或胃肠毒性。西诺沙星似乎是治疗由肠杆菌科细菌引起的尿路感染的一种安全有效的药物。
